

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/17/2025	10808165-00008	Date of first issue: 07/05/2022

### SECTION 1. IDENTIFICATION

Product name : Levamisole / Oxfendazole Formulation  
Other means of identification : Scanda (A007130)

#### Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc  
Address : 37 McCarville Street  
Charlottetown, PE C1E 2A7  
Telephone : 908-740-4000  
Emergency telephone : 1-908-423-6000  
E-mail address : EHSDATASTEWARD@merck.com

#### Recommended use of the chemical and restrictions on use


Recommended use : Veterinary product  
Restrictions on use : Not applicable

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the Hazardous Products Regulations

Reproductive toxicity : Category 1B  
  
Specific target organ toxicity : Category 2 (Liver, Testis)  
- repeated exposure  
  
Specific target organ toxicity : Category 2 (Blood, Testis)  
- repeated exposure (Oral)

#### GHS label elements

Hazard pictograms	: 
Signal Word	: Danger
Hazard Statements	: H360FD May damage fertility. May damage the unborn child. H373 May cause damage to organs (Liver, Testis) through prolonged or repeated exposure. H373 May cause damage to organs (Blood, Testis) through prolonged or repeated exposure if swallowed.
Precautionary Statements	: <b>Prevention:</b> P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe mist or vapors. P280 Wear protective gloves, protective clothing, eye protection and face protection.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole / Oxfendazole Formulation

Version 4.0      Revision Date: 06/17/2025      SDS Number: 10808165-00008      Date of last issue: 04/14/2025  
Date of first issue: 07/05/2022

### Response:

P308 + P313 IF exposed or concerned: Get medical attention.

### Storage:

P405 Store locked up.

### Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

### Other hazards

None known.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Levamisole hydrochloride	No data available	16595-80-5	$\geq 5 - < 10$ *
oxfendazole	No data available	53716-50-0	$\geq 1 - < 5$ *
Polyethylene glycol stearate	Ethoxylated stearic acid	9004-99-3	$\geq 1 - < 5$ *
Citric acid	2-hydroxypropane-1,2,3-tricarboxylic acid	77-92-9	$\geq 1 - < 5$ *

\* Actual concentration or concentration range is withheld as a trade secret

## SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/17/2025	10808165-00008	Date of first issue: 07/05/2022

Most important symptoms and effects, both acute and delayed	:	May damage fertility. May damage the unborn child. May cause damage to organs through prolonged or repeated exposure.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole / Oxfendazole Formulation

Version 4.0      Revision Date: 06/17/2025      SDS Number: 10808165-00008      Date of last issue: 04/14/2025  
Date of first issue: 07/05/2022

container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
Do not breathe mist or vapors.  
Do not swallow.  
Avoid contact with eyes.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.  
Store locked up.  
Keep tightly closed.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Levamisole hydrochloride	16595-80-5	TWA	20 µg/m <sup>3</sup> (OEB 3)	Internal
	Further information: Skin			
		Wipe limit	200 µg/100 cm <sup>2</sup>	Internal
oxfendazole	53716-50-0	TWA	40 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	400 µg/100 cm <sup>2</sup>	Internal
Polyethylene glycol stearate	9004-99-3	TWA	10 mg/m <sup>3</sup>	CA AB OEL
		TWA (Inhalable)	10 mg/m <sup>3</sup>	CA BC OEL

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole / Oxfendazole Formulation

Version 4.0      Revision Date: 06/17/2025      SDS Number: 10808165-00008      Date of last issue: 04/14/2025  
Date of first issue: 07/05/2022

		TWA (Respirable)	3 mg/m <sup>3</sup>	CA BC OEL
		TWAEV (inhalable dust)	10 mg/m <sup>3</sup>	CA QC OEL
		TWAEV (respirable aerosol fraction)	3 mg/m <sup>3</sup>	CA QC OEL
		TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

### Personal protective equipment

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Particulates type

**Hand protection**

**Material** : Chemical-resistant gloves

**Remarks** : Consider double gloving.

**Eye protection** : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

**Hygiene measures** : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/17/2025	10808165-00008	Date of first issue: 07/05/2022

working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	Aqueous solution
Color	:	No data available
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/17/2025	10808165-00008	Date of first issue: 07/05/2022

Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics		
Particle size	:	Not applicable

### SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
---------------------	---	--

#### Components:

##### Levamisole hydrochloride:

Acute oral toxicity	:	LD50 (Rat): 180 mg/kg LD50 (Mouse): 223 mg/kg LD50 (Rabbit): 458 mg/kg
---------------------	---	--

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/17/2025	10808165-00008	Date of first issue: 07/05/2022

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

### oxfendazole:

Acute oral toxicity : LD50 (Rat): > 6,000 mg/kg

LD50 (Dog): 1,600 mg/kg

LD50 (sheep): 250 mg/kg

### Polyethylene glycol stearate:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

### Citric acid:

Acute oral toxicity : LD50 (Mouse): 5,400 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity

### Skin corrosion/irritation

Not classified based on available information.

### Components:

#### Levamisole hydrochloride:

Remarks : No data available

#### oxfendazole:

Species : Rabbit

Result : No skin irritation

#### Polyethylene glycol stearate:

Species : Rabbit

Method : Draize Test

Result : No skin irritation

#### Citric acid:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

### Serious eye damage/eye irritation

Not classified based on available information.



# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/17/2025	10808165-00008	Date of first issue: 07/05/2022

### Components:

#### **Levamisole hydrochloride:**

Remarks : No data available

#### **oxfendazole:**

Species : Rabbit  
Result : No eye irritation

#### **Polyethylene glycol stearate:**

Species : Rabbit  
Result : No eye irritation  
Method : Draize Test

#### **Citric acid:**

Species : Rabbit  
Result : Irritation to eyes, reversing within 21 days  
Method : OECD Test Guideline 405

### **Respiratory or skin sensitization**

#### **Skin sensitization**

Not classified based on available information.

#### **Respiratory sensitization**

Not classified based on available information.

### Components:

#### **Levamisole hydrochloride:**

Remarks : No data available

#### **Polyethylene glycol stearate:**

Test Type : Open epicutaneous test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Result : negative

#### **Germ cell mutagenicity**

Not classified based on available information.

### Components:

#### **Levamisole hydrochloride:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
  
Test Type: Chromosome aberration test in vitro  
Result: negative

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/17/2025	10808165-00008	Date of first issue: 07/05/2022

### oxfendazole:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Genotoxicity in vivo	: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Mouse Application Route: Oral Result: positive

### Polyethylene glycol stearate:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	--

### Citric acid:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative  Test Type: in vitro micronucleus test Result: positive  Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Genotoxicity in vivo	: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Rat Application Route: Ingestion Result: negative

### Carcinogenicity

Not classified based on available information.

### Components:

#### Levamisole hydrochloride:

Species	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
NOAEL	: 80 mg/kg body weight
Remarks	: No significant adverse effects were reported

Species	: Rat
Application Route	: Oral
Exposure time	: 2 Years
NOAEL	: 40 mg/kg body weight
Remarks	: No significant adverse effects were reported

### oxfendazole:

Species	: Rat
Application Route	: Oral

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/17/2025	10808165-00008	Date of first issue: 07/05/2022

Exposure time	: 1 Years
Symptoms	: No adverse effects.
Target Organs	: Liver

Species	: Rat
Application Route	: Oral
Exposure time	: 2 Years
Symptoms	: No adverse effects.
Target Organs	: Liver

### Reproductive toxicity

May damage fertility. May damage the unborn child.

### Components:

#### Levamisole hydrochloride:

Effects on fertility	: Test Type: Three-generation reproduction toxicity study Species: Rat Application Route: Oral Result: No significant adverse effects were reported
Effects on fetal development	: Test Type: Embryo-fetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 20 mg/kg body weight Result: Fetotoxicity.  Test Type: Embryo-fetal development Species: Rabbit Application Route: Oral Developmental Toxicity: LOAEL: 40 mg/kg body weight Result: Fetotoxicity.
Reproductive toxicity - Assessment	: Some evidence of adverse effects on development, based on animal experiments.

#### oxfendazole:

Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rat, male Application Route: Oral Fertility: NOAEL: 17 mg/kg body weight Target Organs: Testes Result: Effects on fertility.  Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Fertility: NOAEL: 0.9 mg/kg body weight Target Organs: Liver Result: No effects on fertility.  Test Type: Fertility Species: Mouse
----------------------	--

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/17/2025	10808165-00008	Date of first issue: 07/05/2022

	Application Route: Oral Duration of Single Treatment: 1 Months Fertility: NOAEL: 750 mg/kg body weight Target Organs: Testes Result: Effects on fertility.
Effects on fetal development	: Test Type: Embryo-fetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: positive, Fetal effects.  Test Type: Embryo-fetal development Species: Rat Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: positive, Embryo-fetal toxicity.  Test Type: Embryo-fetal development Species: Mouse Application Route: Oral Developmental Toxicity: NOAEL: 108 mg/kg body weight Result: positive, Embryo-fetal toxicity., Fetal abnormalities.  Test Type: Embryo-fetal development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 0.625 mg/kg body weight
Reproductive toxicity - Assessment	: Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

### Citric acid:

Effects on fetal development	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
------------------------------	---

### STOT-single exposure

Not classified based on available information.

### Components:

#### Citric acid:

Assessment	: May cause respiratory irritation.
------------	-------------------------------------

### STOT-repeated exposure

May cause damage to organs (Liver, Testis) through prolonged or repeated exposure.  
May cause damage to organs (Blood, Testis) through prolonged or repeated exposure if swallowed.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole / Oxfendazole Formulation

Version 4.0      Revision Date: 06/17/2025      SDS Number: 10808165-00008      Date of last issue: 04/14/2025  
Date of first issue: 07/05/2022

### Components:

#### **Levamisole hydrochloride:**

Target Organs : Blood, Testis  
Assessment : May cause damage to organs through prolonged or repeated exposure.

#### **oxfendazole:**

Routes of exposure : Oral  
Target Organs : Liver, Testis  
Assessment : May cause damage to organs through prolonged or repeated exposure.

### **Repeated dose toxicity**

### Components:

#### **Levamisole hydrochloride:**

Species : Rat  
NOAEL : 2.5 mg/kg  
Application Route : Oral  
Exposure time : 18 Months  
Target Organs : Testis

Species : Dog  
LOAEL : 20 mg/kg  
Application Route : Oral  
Exposure time : 18 Months  
Target Organs : Blood

Species : Dog  
LOAEL : 40 mg/kg  
Application Route : Oral  
Exposure time : 3 Months

#### **oxfendazole:**

Species : Rat  
NOAEL : 11 mg/kg  
Application Route : Oral  
Exposure time : 2 Weeks  
Target Organs : Blood, Liver, Testis

Species : Rat  
NOAEL : 3.8 mg/kg  
Application Route : Oral  
Exposure time : 3 Months  
Target Organs : Liver, Testis

Species : Mouse  
NOAEL : 750 mg/kg  
Application Route : Oral  
Exposure time : 1 Months

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/17/2025	10808165-00008	Date of first issue: 07/05/2022

|| Target Organs : Liver

|| Species : Mouse  
|| NOAEL : 37.5 mg/kg  
|| Application Route : Oral  
|| Exposure time : 3 Months  
|| Target Organs : Liver

|| Species : Dog  
|| NOAEL : 6 mg/kg  
|| Application Route : Oral  
|| Exposure time : 1 Months  
|| Remarks : No significant adverse effects were reported

|| Species : Dog  
|| NOAEL : 11 mg/kg  
|| Application Route : Oral  
|| Exposure time : 2 Weeks  
|| Target Organs : Lymph nodes, thymus gland

|| Species : Dog  
|| NOAEL : 13.5 mg/kg  
|| Application Route : Oral  
|| Exposure time : 12 Months  
|| Target Organs : Liver

### Citric acid:

|| Species : Rat  
|| NOAEL : 4,000 mg/kg  
|| LOAEL : 8,000 mg/kg  
|| Application Route : Ingestion  
|| Exposure time : 10 Days

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

### Components:

#### Levamisole hydrochloride:

|| Ingestion : Symptoms: Nausea, Vomiting, Headache, Dizziness, hypotension

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

### Components:

#### Levamisole hydrochloride:

|| Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 37.3 mg/l  
Exposure time: 96 h

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/17/2025	10808165-00008	Date of first issue: 07/05/2022

Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 64 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

### oxfendazole:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 2.7 mg/l  
Exposure time: 96 h  
LC50 (Oncorhynchus mykiss (rainbow trout)): > 2.5 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.059 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.023 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

### Polyethylene glycol stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 10,000 mg/l  
Exposure time: 96 h  
Method: DIN 38412

Toxicity to microorganisms : EC10 (Bacteria): > 10,000 mg/l  
Exposure time: 16 h

### Citric acid:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,535 mg/l  
Exposure time: 24 h

### Persistence and degradability

#### Components:

#### oxfendazole:

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/17/2025	10808165-00008	Date of first issue: 07/05/2022

Stability in water : Hydrolysis: < 5 % (4 d)

### Polyethylene glycol stearate:

Biodegradability : Result: Readily biodegradable.  
Biodegradation: > 70 %  
Exposure time: 10 d  
Method: OECD Test Guideline 302B

### Citric acid:

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 97 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301B

### Bioaccumulative potential

#### Components:

##### oxfendazole:

Partition coefficient: n-octanol/water : log Pow: 1.95

##### Citric acid:

Partition coefficient: n-octanol/water : log Pow: -1.72

### Mobility in soil

#### Components:

##### oxfendazole:

Distribution among environmental compartments : log Koc: 3.2

### Other adverse effects

No data available

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

UN number : UN 3082



# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/17/2025	10808165-00008	Date of first issue: 07/05/2022

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(oxfendazole)

Class : 9  
Packing group : III  
Labels : 9  
Environmentally hazardous : yes

### IATA-DGR

UN/ID No. : UN 3082  
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.  
(oxfendazole)

Class : 9  
Packing group : III  
Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 964  
Packing instruction (passenger aircraft) : 964  
Environmentally hazardous : yes

### IMDG-Code

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(oxfendazole)  
Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### Domestic regulation

#### TDG

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(oxfendazole)  
Class : 9  
Packing group : III  
Labels : 9  
ERG Code : 171  
Marine pollutant : yes(oxfendazole)

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/17/2025	10808165-00008	Date of first issue: 07/05/2022

### SECTION 15. REGULATORY INFORMATION

**The ingredients of this product are reported in the following inventories:**

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

### SECTION 16. OTHER INFORMATION

#### Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
CA AB OEL	:	Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)
CA BC OEL	:	Canada. British Columbia OEL
CA QC OEL	:	Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants
ACGIH / TWA	:	8-hour, time-weighted average
CA AB OEL / TWA	:	8-hour Occupational exposure limit
CA BC OEL / TWA	:	8-hour time weighted average
CA QC OEL / TWAEV	:	Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transporta-

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/17/2025	10808165-00008	Date of first issue: 07/05/2022

---

tion of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 06/17/2025  
Date format : mm/dd/yyyy

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8